AIMD vs AEYE vs XTLB vs SABS vs NNOX

For growth investors, AudioEye, Inc.

(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -100. 0% for SAB Biotherapeutics, Inc. (SABS). Analysts rate SAB Biotherapeutics, Inc. (SABS) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AudioEye, Inc.

(AEYE) delivered a total return of -60. 2%, compared to -99. 4% for Ainos, Inc. (AIMD). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus AIMD's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SAB Biotherapeutics, Inc.

(SABS) is the lower-risk stock at 0. 80β versus Ainos, Inc. 's 2. 54β — meaning AIMD is approximately 218% more volatile than SABS relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 77% for Ainos, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AudioEye, Inc.

(AEYE) is pulling ahead at 14. 5% versus -100. 0% for SAB Biotherapeutics, Inc. (SABS). On earnings-per-share growth, the picture is similar: SAB Biotherapeutics, Inc. grew EPS 78. 5% year-over-year, compared to 15. 7% for Nano-X Imaging Ltd.. Over a 3-year CAGR, NNOX leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SAB Biotherapeutics, Inc.

(SABS) is the more profitable company, earning 0. 0% net margin versus -717. 0% for Ainos, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SABS leads at 0. 0% versus -667. 7% for AIMD. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, SAB Biotherapeutics, Inc.

(SABS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80)). Ainos, Inc. (AIMD) carries a higher beta of 2. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SABS: -96. 0%, AIMD: -97. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AIMD (Healthcare) and AEYE (Technology) and XTLB (Healthcare) and SABS (Healthcare) and NNOX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.